Streptomyces antibioticus No. B-1625, isolated from Mt. Aso in KumamotoPrefecture, is a typical actinomycin producer and produces a small amount of acidic actinomycin congeners (FA-components) in addition to actinomycin X2, D, and XOiJ.1) Among the FA-components, selectively increased production of FA2j8 was devised,2) and the structure of FA2/j-! was deduced to be 2-amino-lcarboxyl-3-phenoxazone-9-carbonyl-threonylvalyl-sarcosyl-sarcosyl-7V-methylvaline. 3) Because the lack of antibiotic activity of FA2£_ l5 the isolation of active FA components is continuing.
The FA-components were various minor ones. Increased production of antibiotics after protoplast regeneration has been reported4'5) and in addition, new antibiotics have been reported to be produced by interspecific fusion6) and crosses.7) Intraspecific recombination in antibiotic-producing streptomycetes is well known8) and is theoretically suitable for strain improvement.9)
Wetried intraspecific fusion of the comple- and their antibiotic productivity.
Materials and Methods
Strains. The wild type strain of S. antibioticus B-1625 was treated with Af-methyl-jV'-nitro-iV-nitrosoguanidine 1 0) to obtain different auxotrophic mutants. The mutant 194 requires adenine, guanine, and hypoxanthine. The mutant llM-21 which produces a large amount of FAcomponents, was also an auxotrophic mutant requiring tyrosine, glutamic acid, aspartic acid, and histidine.
Media. Minimal medium (MM) was composed of glycerine, 1.0%; ammonium succinate, 0.1%; NaCl, 0.5%; MgSO4-7H2O, 0.05%; K2HPO4, 0.05%; and Bacto-agar (Difco), 2.0%. 
Preparation ofProtoplasts.
Each strain, incubated for 2 days in the FA-production medium at 28°C was inoculated into the same medium supplemented with 0.8% glycine. After further incubation for 2 days, protoplasts were prepared by the method of Okanishi et al.11 ] The strains were incubated with 2.5mg/ml of lysozyme at 30°C for 60min and about 2 x 107~8 protoplast cells were obtained from 50ml of culture broth.
Fusion treatment. Protoplasts (approximately 2 x 107~8) from each of the two strains were suspended in 0.1 ml of mediumP1 1} and incubated for 1 min at room temperature after mixing with 0.9ml of 42% PEG 4000 solution.
Protoplast regeneration with or without fusion treatment. Characterization of the antibiotic produced by strain F-40. The strain F-40, a regenerated clone obtained by fusion treatment, was grown in 125ml of medium containing starch, 1.0%; malt extract, 1.0%; yest extract, 0.4%, in 500-ml Sakaguchi flasks with reciprocal shaking for 40 hr at 28°C. The filtrate of culture broth (pH 6.0) was extracted three times with a 1/3 volume of benzene. After dehydration with anhydrous Na2SO4the benzene extract was evaporated under N2 gas in vacuo to give an yellowish oil of crude antibiotic F-40. The crude antibiotic was put on a cellulose TLCplate and then developed with benzene saturated with water. The band that inhibited E. coli in the thin layer chromatogram was cut out and extracted with acetone. The solvent extract was evaporated under N2 gas in vacuo to give a greenish-yellow oil. The physico-chemical properties of antibiotic F-40 are shown in Table III , compared with those of actinomycin D, which was produced by the parent strain. F-40 is a quite labile, light yellow wax-like solid. Based on the results of amino acid analysis, it was considered to be a for it was not obtained, probably due to its lability.
As shown in Table IV , F-40 was active against Gram-positive and Gram-negative bacteria, while actinomycin D is active only against Gram-positive bacteria. As described above, the antibiotic F-40 was clearly differentiated from actinomycins by its antibiotic spectrum, amino acid composition, Rf values, and UV-, IR-, FAB-MS spectra. From these findings it was supposed to be a new peptide antibiotic.
Detailed structural studies on F-40 are the subject of future work.
Discussion
During our experiments on protoplast regeneration, strain F-40, the progeny of a clone regenerated after fusion treatment, was found to be a prototroph and to produce a different antibiotic from those produced by the sidered to be generated after such a mutational alteration and DNAamplification. The production of a distinct antibiotic, may be a new type, by the regenerated clones was quite interesting, although the chemical structure of the antibiotic and the mechanismof antibiotic production are still to be discovered.
